Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. — Stella
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
(75 sites) United States
University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama City of Hope, Duarte, California USC Norris Comprehensive Cancer Center, Los Angeles, California California Pacific Medical Center, San Francisco, California University of Colorado Cancer Center, Aurora, Colorado Orlando Health Cancer Institute, Orlando, Florida University of Illinois Hospital & Health Sciences System, Chicago, Illinois University of Kansas, Kansas City, Kansas University of Louisville - James Graham Brown Cancer Center, Louisville, Kentucky National Cancer Institute, Bethesda, Maryland Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit, Michigan Henry Ford Health, Detroit, Michigan Dartmouth-Hitchcock Medical Center (DHMC) - Norris Cotton Cancer Center, Lebanon, New Hampshire MD Anderson Cancer Center at Cooper, Camden, New Jersey Oncology Hematology Care, Cincinnati, Ohio Ohio State University, Columbus, Ohio St. Luke's Cancer Center - Anderson, Easton, Pennsylvania Allegheny Health Network, Pittsburgh, Pennsylvania Baptist Cancer Center, Bartlett, Tennessee SCRI Oncology Partners, Nashville, Tennessee Virginia Commonwealth University, Richmond, Virginia Swedish Cancer Institute, Edmonds, Washington Australia
Greenslopes Private Hospital, Greenslopes, Queensland Peter MacCallum Cancer Centre, Melbourne, Victoria Fiona Stanley Hospital, Murdoch, Western Australia Flinders Medical Centre, Bedford Park Westmead Hospital, Westmead Belgium
Universitair Ziekenhuis Brussel - Oncologisch Centrum, Jette Canada
Centre hospitalier de l'Université de Montréal, Montreal, Quebec Princess Margaret Cancer Centre, Toronto France
Institut Paoli Calmettes, Marseille Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu, Nantes Hopital Saint Louis, Paris Germany
Charité - Universitätsmedizin Berlin, Berlin, Germany Universitätsklinikum Carl Gustav Carus, Dresden Universitätsklinikum Hamburg-Eppendorf, Hamburg Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck Klinikum Rechts der Isar der Technischen Universität München, Munich Israel
Hadassah Medical Center, Jerusalem Sheba Medical Center, Ramat Gan Tel Aviv Sourasky Medical Center, Tel Aviv Italy
Istituto Romagnolo per lo Studio dei Tumori, Meldola, Forlì-Cesena Centro di Riferimento Oncologico IRCCS, Aviano, Friuli Venezia Giulia Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Naples, Napoli Azienda Ospedaliero Universitaria Pisana, Pisa, Tuscany Istituto Europeo Di Oncologia, Milan Azienda Ospedaliera Universitaria Senese, Siena Netherlands
Nederlands Kanker Instituut, Amsterdam South Korea
Bundang Medical Center - CHA University, Seongnam-si, Gyeonggi-do Samsung Medical Center, Seoul, South Korea Korea University Anam Hospital, Seoul Seoul National University Hospital, Seoul Severance Hospital, Yonsei University Health System, Seoul Spain
Hospital Universitario Marques de Valdecilla, Santander, Cantabria Hospital Regional Universitario de Malaga - Hospital General, Málaga, Málaga Instituto Oncologico Rosell, Barcelona Hospital Universitari Vall dHebron, Barcelona Hospital Clinic de Barcelona, Barcelona ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona Hospital General Universitario Gregorio Maranon, Madrid Hospital 12 de Octubre, Madrid Hospital Universitario Madrid Sanchinarro - CIOCC, Madrid Hospital Universitario Quirónsalud Madrid, Madrid Hospital Universitario Ramon y Cajal, Madrid Clínica Universitaria de Navarra, Pamplona Hospital Universitario Virgen Macarena, Seville
Sweden
Sahlgrenska Universitetssjukhuset, Gothenburg, Västra Götaland County Switzerland
Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne United Kingdom
Queen Elizabeth Hospital Birmingham, Birmingham, England Freeman Hospital, Newcastle upon Tyne, England Royal Marsden Hospital, Chelsea, London Beaston West of Scotland Canter Centre, Glasgow Sarah Cannon Research Institute UK, London
Key details Sponsor
Iovance Biotherapeutics, Inc.
Enrollment target
~670 participants
Primary completion
March 2028
Age range
18 Years – 70 Years
Last updated April 2026
Interested in joining? Consorcio Hospital General Universitario de Valencia, Valencia